Sunesis Pharmaceuticals (SNSS) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil steadies on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights
May 5, 2015 7:01 AM EDTSOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2015. Loss from operations for the three months ended March 31, 2015 was $8.8 million. As of March 31, 2015, cash, cash equivalents and marketable securities totaled $39.8 million.
"Sunesis is committed to improving treatment outcomes of acute myeloid leukemia patients," said Daniel Swisher, Chief Executive Officer of Sunesis. "Working toward this goal, we remain in an active dialogue with the FDA to determine a regulatory path forward in the United States and look forward to... More
